Table 1 Baseline demographics, comorbidities, disease severity, clinical and laboratory findings on admission, microbiology, and antibiotic therapy of the study population
From: Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia
Study population n = 75 | |
|---|---|
Demographics, n. (%) | |
Male | 43 (57) |
Age, median (IQR) years | 75 (59–84) |
Body mass index, median (IQR) | 24 (20–27) |
Healthcare-associated pneumonia | 5 (7) |
Comorbidities, n. (%) | |
Active neoplastic disease | 12 (16) |
Chronic obstructive pulmonary disease | 18 (24) |
Diabetes mellitus | 11 (15) |
Cerebrovascular accident | 9 (12) |
Liver disease | 5 (7) |
Neurological diseases | 11 (15) |
Renal disease | 8 (11) |
Chronic renal failure | 6 (8) |
Family history of coronary artery disease | 16 (21) |
Essential arterial hypertension | 36 (48) |
Congestive heart failure | 7 (9) |
Active coronary artery disease | 12 (16) |
Prior acute myocardial infarction | 10 (13) |
Atrial fibrillation | 2 (3) |
Hyperlipidemia | 14 (19) |
Medications before admission, n. (%) | |
Aspirin | 17 (23) |
Beta-blockers | 13 (17) |
Angiotensin-converting-enzyme inhibitors | 14 (19) |
Antiplatelets | 8 (11) |
Statins | 12 (16) |
Severity on admission, n. (%) | |
Mental status change | 4 (5) |
PSI Risk Class IV and V | 54 (72) |
PSI Risk Class V | 21 (28) |
Acute respiratory failure | 39 (52) |
Severe sepsis | 14 (19) |
Clinical and laboratory data on admission, median (IQR) | |
Heart rate, bpm | 80 (71–92) |
Respiratory rate, bpm | 20 (18–25) |
Systolic blood pressure, mmHg | 128 (115–146) |
Diastolic blood pressure, mmHg | 70 (60–80) |
White blood cells, cell/L−1 | 11,840 (9180–15,900) |
Hemoglobin, g/dL | 12.6 (11–14.2) |
Hematocrit, % | 37 (33–41) |
Albumin, g/dL | 3.3 (3.1–3.8) |
Platelets, cell/L−1 | 196,000 (161,000–289,000) |
Lactate dehydrogenase, mg/dL | 378 (318–444) |
Blood urea nitrogen, mg/dL | 40 (27–49) |
Creatinine, mg/dL | 1 (0.8–1.3) |
Sodium, mEq/L | 136 (133–139) |
Potassium, mEq/L | 4 (3.7–4.4) |
Glucose, mg/dL | 119 (106–146) |
C-reactive protein, mg/L | 12.9 (6.25–28.8) |
pH | 7.46 (7.44–7.48) |
Microbiology, n. (%) | |
Isolated pathogen | 13 (17) |
S. pneumoniae | 8 (11) |
S. aureus | 2 (3) |
Legionella pneumophila | 2 (3) |
P. aeruginosa | 1 (1) |
Empiric antibiotic treatment, n. (%) | |
Ceftriaxone | 36 (48) |
Azithromycin | 38 (51) |
Levofloxacin | 32 (43) |
Ceftazidime | 8 (11) |
Piperacillin/tazobactam | 9 (12) |
Others | 23 (30) |